BioIVT

BioIVT

BioIVT operates as a specialized provider of biological products and research services. The firm's focus lies in supplying high-quality human and animal tissues, cells, blood products, and other biomaterials to biotechnology and pharmaceutical companies. Its core business supports preclinical research, biomarker discovery, drug metabolism studies, and in vitro diagnostic development. The company maintains a network of donor programs and clinical collection sites, enabling access to ethically sourced, clinically annotated specimens. BioIVT's client base spans academic institutions and large pharmaceutical sponsors seeking reliable biological inputs for regulated research environments. The firm's model integrates biospecimen procurement, laboratory processing, and cold-chain logistics into a streamlined supply chain. BioIVT provides hepatocytes, subcellular fractions, and tissue microarrays, alongside custom cell isolation and characterization services. By managing donor consent, collection, and quality control in-house, the firm reduces batch variability for repeatable experimental outcomes. Its operations support absorption, distribution, metabolism, and excretion (ADME) toxicology studies, as well as cell-based assays critical to compound screening. In 2021, the firm acquired PrecisionMed, expanding its stable of clinical remnant samples and physical biorepository assets. BioIVT's scale derives from aggregated procurement across multiple geographies, though financial specifics remain undisclosed. The firm maintains processing laboratories and logistics hubs in North America and Europe, serving end markets primarily composed of pharmaceutical R&D groups and contract research organizations. Recent operational moves include integrating digital catalog systems to allow real-time inventory queries for academic and industry labs. Chief Executive Officer Gitte Pedersen has emphasized building a quality-centric reputation through certifications and donor-diversity expansion. Structurally, BioIVT occupies a logistics-and-quality niche between donor populations and drug sponsors, reducing procurement friction for researchers. Its architecture relies on centrally managed biorepositories paired with just-in-time processing — a differentiator from project-basis procurement shops. The firm's long-term commercial posture centers on becoming an outsourced procurement utility, allowing drug developers to bypass the regulatory and operational burden of building their own donor networks.